论文部分内容阅读
目的探讨黛力新辅助治疗心肌梗死(MI)合并情感障碍对患者心功能的影响及作用机制。方法将92例MI后合并情感障碍患者随机分为两组:对照组(n=46)给予MI常规治疗,观察组(n=46)在对照组基础上加用黛力新治疗。比较两组治疗前及治疗2周后的心功能指标、汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)评分、血清ET-1、PAI-1、hs-CR、AngⅡ水平变化。结果治疗后观察组的HAMA评分、HAMD评分、血清ET-1、PAI-1、hs-CR、AngⅡ水平显著低于治疗前及对照组,LVEF、CO、SV显著高于治疗前及对照组(P<0.05)。结论黛力新能够有效改善MI后情感障碍患者的焦虑抑郁症状及心功能,其可能机制与下调血清ET-1、PAI-1、hsCR、AngⅡ水平有关。
Objective To investigate the effect and mechanism of Deanxit adjuvant treatment on cardiac function in patients with myocardial infarction (MI) complicated with affective disorder. Methods 92 patients with post-MI complicated with affective disorder were randomly divided into two groups: the control group (n = 46) was given routine treatment of MI, and the observation group (n = 46) was treated with deacetylene on the basis of the control group. HAMA, HAMD scores, serum ET-1, PAI-1, hs-CR and AngⅡ levels in both groups before and after 2 weeks of treatment were compared. Results After treatment, the HAMA score, HAMD score, serum ET-1, PAI-1, hs-CR and AngⅡ in the observation group were significantly lower than those before treatment and in the control group P <0.05). Conclusions Deanxit can effectively alleviate the anxiety and depression symptoms and cardiac function in patients with affective disorder after MI. The possible mechanism is related to the decrease of serum ET-1, PAI-1, hsCR and AngⅡ.